Glucotrack Achieves Key Milestones in CGM Development

Introduction to GLUCOTRACK INC

GLUCOTRACK INC (Nasdaq: GCTK; Korean name: 글루코트랙) is a medical technology company headquartered in Rutherford, New Jersey, with a research and development facility in Ashdod, Israel. The company focuses on developing a fully implantable Continuous Blood Glucose Monitoring (CBGM) system that measures glucose directly from blood, eliminating external wearable components.

Corporate Structure and Leadership

Under the leadership of President and Chief Executive Officer Paul V. Goode, PhD, Glucotrack operates as a Delaware corporation. The board of directors expanded on May 22, 2025, with the election of Victoria E. Carr-Brendel, PhD, a medical device executive with experience in implantable technologies. In May 2025, Glucotrack formed a Patient Advisory Council to involve end users in the development of its CBGM system.

Recent Developments and News

Since March 2025, Glucotrack has announced several milestones:

• March 19–22, 2025: Presentation of first-in-human CBGM safety and performance data at the ATTD conference in Amsterdam.
• March 31, 2025: Annual report indicated the transition from preclinical to clinical stage and projected Investigational Device Exemption (IDE) submission in Q4 2025.
• April 3, 2025: Partnership with OneTwo Analytics to apply AI-driven insights to clinical study data.
• April 16, 2025: Collaboration announced to integrate CBGM with an automated insulin delivery system for a major EU diabetes study.
• May 13, 2025: Ethical approval received from St. Vincent’s for a long-term multicenter feasibility study.
• May 14, 2025: Plan disclosed to implant first patients in Australia in Q3 2025.
• May 20, 2025: Establishment of a Patient Advisory Council to guide clinical development.
• May 28, 2025: Victoria E. Carr-Brendel, PhD, joined the board.
• June 12, 2025: Announcement of a 1-for-60 reverse stock split effective June 16, 2025.
• June 25, 2025: Press release detailed a comprehensive analysis showing a Mean Absolute Relative Difference (MARD) of 7.7% for Glucotrack’s CGM technology.

Financial and Strategic Analysis

As of June 25, 2025, GCTK shares closed at $8.81, an increase of 41.87% on a volume of 1,517,588. A 1-for-60 reverse stock split took effect on June 16, 2025, consolidating outstanding shares to meet Nasdaq requirements. The company remains in the clinical and investigational phase—currently without revenue streams—while its strategic focus is on advancing the CBGM through FDA IDE approval in Q4 2025 and initiating chronic implant studies in Australia in Q3 2025. Collaborations with analytics and automated insulin delivery providers reflect Glucotrack’s effort to compete in the continuous glucose monitoring market by providing real-time blood glucose readings without external components.

Ticker	Exchange	Price (6/25/2025)	Change (%)	Volume
GCTK	NASDAQ	$8.81	+41.87	1,517,588

Market Position and Industry Context

The prevalence of diabetes globally is rising, resulting in increased demand for convenient and accurate glucose monitoring solutions. The current CGM market predominantly features interstitial-fluid devices from established entities. Glucotrack’s investigational, implantable CBGM system—designed for up to three years of continuous use—addresses limitations such as lag time and wearability issues. Key regulatory milestones, including an IDE submission expected in Q4 2025 and initial patient implants set for Q3 2025, will impact Glucotrack’s competitiveness in a market that is moving towards less intrusive and more precise monitoring options.

tl;dr

On June 25, 2025, GCTK stock increased 41.87% to $8.81 following a press release that reported a MARD of 7.7% for its implantable glucose monitor. A 1-for-60 reverse stock split took effect on June 16, 2025. The company plans to implant its first patients in Australia in Q3 2025 and aims for FDA IDE approval in Q4 2025, positioning its CBGM technology for investigational use ahead of potential commercialization.